Literature DB >> 28110949

Prophylactic Effect of Oral Acetazolamide against Intraocular Pressure Elevation after Cataract Surgery in Eyes with Glaucoma.

Ken Hayashi1, Motoaki Yoshida2, Shin-Ichi Manabe2, Koichi Yoshimura2.   

Abstract

PURPOSE: To confirm the prophylactic effect of oral acetazolamide against increased intraocular pressure (IOP) in the period immediately after cataract surgery in eyes with primary open-angle glaucoma (POAG) and to evaluate the appropriate administration time of oral acetazolamide to prevent IOP elevation.
DESIGN: Randomized clinical study. PARTICIPANTS: Ninety eyes of 90 patients with well-controlled POAG scheduled for phacoemulsification.
METHODS: Eyes were assigned randomly to 1 of 3 groups: (1) oral acetazolamide (500 mg) administration 1 hour preoperatively, (2) oral acetazolamide (500 mg) administration 3 hours postoperatively, or (3) no acetazolamide administration. Intraocular pressure was measured using a rebound tonometer 1 hour preoperatively, at the conclusion of surgery (adjusted in the range between 15 and 25 mmHg), and 1, 3, 5, 7, and 24 hours postoperatively. The incidence of eyes with IOP elevation more than 100% above the preoperative IOP was compared. MAIN OUTCOME MEASURES: Postoperative IOP and incidence of eyes with marked IOP elevation.
RESULTS: Mean IOP 1 hour preoperatively and that at the conclusion of surgery did not differ significantly among groups. In all groups, mean IOP was significantly elevated from 3 to 7 hours postoperatively, and then decreased at 24 hours. At 1 and 3 hours postoperatively, mean IOP was significantly lower in the group receiving oral acetazolamide preoperatively than in the other 2 groups (postoperative administration or no administration; P ≤ 0.0031). At 5, 7, and 24 hours postoperatively, the IOP was significantly lower in both the preoperative and postoperative administration groups than in the nonadministration group (P ≤ 0.0224). Intraocular pressure elevation of more than 100% occurred in 1 eye (3.3%) in the preoperative administration group, 7 eyes (23.3%) in the postoperative administration group, and 8 eyes (26.6%) in the nonadministration group; the incidence was significantly lower in the preoperative administration group (P = 0.0459).
CONCLUSIONS: Eyes with POAG experienced short-term IOP elevation from 3 to 7 hours after phacoemulsification. Oral acetazolamide administration 1 hour preoperatively significantly reduced the IOP elevation from 1 to 24 hours, while administration 3 hours postoperatively reduced the IOP elevation at 5 hours or more after surgery.
Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28110949     DOI: 10.1016/j.ophtha.2016.12.027

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

1.  Carbonic anhydrase inhibition improves pulmonary artery reactivity and nitric oxide-mediated relaxation in sugen-hypoxia model of pulmonary hypertension.

Authors:  Helen Christou; Zoe Michael; Fotios Spyropoulos; Yunfei Chen; Dan Rong; Raouf A Khalil
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-04-07       Impact factor: 3.210

Review 2.  A Review of Complicated Cataract in Retinitis Pigmentosa: Pathogenesis and Cataract Surgery.

Authors:  Yingying Hong; Hongzhe Li; Yang Sun; Yinghong Ji
Journal:  J Ophthalmol       Date:  2020-12-21       Impact factor: 1.909

Review 3.  Surgical and Perioperative Considerations for the Treatment of Cataract in Eyes with Glaucoma: A Literature Review.

Authors:  Kleonikos Tsakiris; George Kontadakis; Panagiotis Georgoudis; Zisis Gatzioufas; Athanasios Vergados
Journal:  J Ophthalmol       Date:  2021-04-26       Impact factor: 1.909

4.  Contribution of prostanoid FP receptor and prostaglandins in transient inflammatory ocular hypertension.

Authors:  Reiko Yamagishi-Kimura; Megumi Honjo; Makoto Aihara
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.